- Home
- ALTO vs BCYC Comparison
ALTO vs BCYC Comparison
Compare ALTO & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALTO | BCYC |
|---|---|---|
| Founded | 2003 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.2M | 360.7M |
| IPO Year | 2005 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ALTO | BCYC |
|---|---|---|
| Price | $4.90 | $4.71 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $13.90 |
| AVG Volume (30 Days) | ★ 1.6M | 398.3K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 119.51 | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $917,927,000.00 | N/A |
| Revenue This Year | $6.66 | N/A |
| Revenue Next Year | $0.43 | N/A |
| P/E Ratio | $27.72 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.80 | $4.24 |
| 52 Week High | $6.00 | $9.36 |
Technical Indicators
Market Signals| Indicator | ALTO | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 48.27 | 43.32 |
| Support Level | $0.98 | $4.52 |
| Resistance Level | $5.07 | $5.41 |
| Average True Range (ATR) | 0.40 | 0.22 |
| MACD | -0.12 | -0.00 |
| Stochastic Oscillator | 33.33 | 25.90 |
Price Performance
Historical ComparisonAbout ALTO Alto Ingredients Inc.
Alto Ingredients Inc is a producer and distributor of specialty alcohols, renewable fuels and essential ingredients in the United States. The company serves five markets: Health, Home and Beauty, Food and Beverage, Essential Ingredients, and Renewable Fuels. Its customers include food and beverage companies and consumer products manufacturers and distributors. The company operates under three segments: Marketing and distribution, Pekin Campus production, and Western production.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.